MARKET

VCEL

VCEL

Vericel
NASDAQ

Real-time Quotes | Nasdaq Last Sale

25.70
0.00
0.00%
After Hours: 25.70 0 0.00% 17:00 06/24 EDT
OPEN
26.13
PREV CLOSE
25.70
HIGH
26.47
LOW
25.34
VOLUME
684.91K
TURNOVER
0
52 WEEK HIGH
68.94
52 WEEK LOW
22.42
MARKET CAP
1.21B
P/E (TTM)
-106.5064
1D
5D
1M
3M
1Y
5Y
Vericel Earnings Perspective: Return On Capital Employed
Benzinga Pro data, Vericel (NASDAQ:VCEL) reported Q1 sales of $36.07 million. Earnings fell to a loss of $7.09 million, resulting in a 256.4% decrease from last quarter. Vericel earned $4.53 million, and sales totaled $47.59 million in Q4.
Benzinga · 05/20 13:49
Vericel Corporation (VCEL) Reports Q1 Loss, Tops Revenue Estimates
Vericel Corporation (VCEL) delivered earnings and revenue surprises of 0% and 6.53%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/04 13:05
Vericel: Q1 Earnings Insights
  Vericel (NASDAQ:VCEL) reported its Q1 earnings results on Wednesday, May 4, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Benzinga · 05/04 12:28
Vericel GAAP EPS of -$0.15 misses by $0.03, revenue of $36.07M beats by $1.76M
Vericel press release (NASDAQ:VCEL): Q1 GAAP EPS of -$0.15 misses by $0.03. Revenue of $36.07M (+4.3% Y/Y) beats by $1.76M. The company reaffirmed financial guidance for FY2022: Total net revenue in
Seekingalpha · 05/04 11:58
Vericel Q1 EPS $(0.15) Misses $(0.12) Estimate, Sales $36.07M Beat $34.31M Estimate
Vericel (NASDAQ:VCEL) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.12) by 25 percent. This is a 114.29 percent decrease over losses of $(0.07) per share from the same
Benzinga · 05/04 11:57
-- Earnings Flash (VCEL) VERICEL CORPORATION Reports Q1 Revenue $36.1M
MT Newswires · 05/04 08:19
Vericel Q1 2022 Earnings Preview
Vericel (NASDAQ:VCEL) is scheduled to announce Q1 earnings results on Wednesday, May 4th, before market open. The consensus EPS Estimate is -$0.12 (-71.4% Y/Y) and the consensus Revenue Estimate is
Seekingalpha · 05/03 15:56
Notable earnings before Wednesday's open
ABC, AMRN, AMRX, ASC, ATI, AVA, AVNS, BDC, BIP, BLX, BRKR, BRY, BWA, CDW, CFMS, CGAU, CLDT, CLH, CLVS, CMLS, CRL, CRTO, CSII, CVS, DCPH, DIN, DOC, OTCPK:EADSF, EAT, EDIT,
Seekingalpha · 05/03 15:43
More
No Data
Learn about the latest financial forecast of VCEL. Analyze the recent business situations of Vericel through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

60.00%Strong Buy
40.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average VCEL stock price target is 47.40 with a high estimate of 53.00 and a low estimate of 36.00.
High53.00
Average47.40
Low36.00
Current 25.70
EPS
Actual
Estimate
-0.08-0.020.050.11
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 279
Institutional Holdings: 66.53M
% Owned: 141.19%
Shares Outstanding: 47.12M
TypeInstitutionsShares
Increased
69
3.36M
New
32
707.96K
Decreased
70
2.72M
Sold Out
20
694.90K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+2.68%
Pharmaceuticals & Medical Research
+2.48%
Key Executives
Non-Executive Chairman/Independent Director
Robert Zerbe
President/Chief Executive Officer/Director
Dominick Colangelo
Chief Financial Officer
Joseph Mara
Chief Operating Officer
Michael Halpin
Senior Vice President/General Counsel/Secretary
Sean Flynn
Chief Accounting Officer
Jonathan Siegal
Other
Jonathan Hopper
Independent Director
Steven Gilman
Independent Director
Heidi Hagen
Independent Director
Kevin Mclaughlin
Independent Director
Alan Rubino
Independent Director
Paul Wotton
Independent Director
Lisa Wright
No Data
No Data
About VCEL
Vericel Corporation is a commercial-stage biopharmaceutical company. The Company is focused on therapies for the sports medicine and severe burn care markets. It markets two autologous cell therapy products in the United States, which include MACI (autologous cultured chondrocytes on porcine collagen membrane) and Epicel (cultured epidermal autografts). MACI is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel is a permanent skin replacement humanitarian use device (HUD) for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns comprising greater than or equal to 30% of total body surface area (TBSA). Its NexoBrid, is a registration-stage, topically administered biological product that enzymatically removes nonviable burn tissue, or eschar, in patients with deep partial and full-thickness thermal burns.

Webull offers kinds of Vericel Corp stock information, including NASDAQ:VCEL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VCEL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VCEL stock methods without spending real money on the virtual paper trading platform.